| P2093 | author name string | Federico Cacciapuoti | |
| P2860 | cites work | Stereospecific in vitro and in vivo effects of the new sinus node inhibitor (+)-S 16257 | Q74121437 |
| | A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group | Q77997669 |
| | Safety and efficacy of extended-release ranolazine in patients aged 70 years or older with chronic stable angina pectoris | Q95818399 |
| | Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina | Q28276346 |
| | Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial | Q28291239 |
| | Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study | Q28291971 |
| | Comparison of the efficacy and tolerability of ivabradine and ranolazine in patients of chronic stable angina pectoris | Q28706249 |
| | Ivabradine: the evidence of its therapeutic impact in angina | Q33973963 |
| | Effects of ivabradine and ranolazine in patients with microvascular angina pectoris | Q34337197 |
| | Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial | Q34544699 |
| | Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina | Q34547211 |
| | Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial | Q34568445 |
| | Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial | Q34569443 |
| | Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial | Q34817084 |
| | Effect of Ranolazine Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes | Q35769527 |
| | Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial | Q35810820 |
| | Clinical practice. Chronic stable angina | Q36164567 |
| | Current-dependent block of rabbit sino-atrial node I(f) channels by ivabradine | Q36452785 |
| | Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine | Q36507053 |
| | Estimating deaths from cardiovascular disease: a review of global methodologies of mortality measurement | Q37016372 |
| | Ivabradine: beyond heart rate control | Q37376067 |
| | Ivabradine: from molecular basis to clinical effectiveness | Q37737147 |
| | Primary coronary microvascular dysfunction: clinical presentation, pathophysiology, and management | Q37762089 |
| | Ivabradine: an intelligent drug for the treatment of ischemic heart disease | Q38060459 |
| | Ivabradine: the hope for a good treatment of ischemic heart disease | Q38080171 |
| | Blockade of Na+ channels in pancreatic α-cells has antidiabetic effects | Q42458638 |
| | Treatment of stable angina pectoris by ivabradine in every day practice: the REDUCTION study | Q43271252 |
| | Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial | Q44319414 |
| | Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes | Q44970567 |
| | Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial | Q46059602 |
| | Ranolazine increases β-cell survival and improves glucose homeostasis in low-dose streptozotocin-induced diabetes in mice | Q46163409 |
| | Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes | Q46715059 |
| | Heart failure in older adults: a conversation with Dr Michael Rich. Interview by Dr Ali Ahmed | Q48553866 |
| | Effects of ivabradine in patients with stable angina receiving β-blockers according to baseline heart rate: an analysis of the ASSOCIATE study | Q48582432 |
| | Ivabradine in stable coronary artery disease without clinical heart failure. | Q53262277 |
| | Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. | Q54159713 |
| | Heart Rate Reduction Induced by the If Current Inhibitor Ivabradine Improves Diastolic Function and Attenuates Cardiac Tissue Hypoxia | Q57189993 |
| | Efficacy of Ivabradine in Combination with Beta-Blocker Versus Uptitration of Beta-Blocker in Patients with Stable Angina | Q57312494 |
| | Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies | Q71461844 |
| P433 | issue | 2 | |
| P304 | page(s) | 98-102 | |
| P577 | publication date | 2016-03-03 | |
| P1433 | published in | Therapeutic advances in cardiovascular disease | Q26842002 |
| P1476 | title | Ranolazine and Ivabradine: two different modalities to act against ischemic heart disease | |
| P478 | volume | 10 | |